Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo Controlled, Phase 2 Trial of Paclitaxel in Combination With AMG 386 in Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cancer
Brief Summary: This study is a phase 2, randomized, double-blind, placebo controlled, multi-center study to estimate the improvement in PFS (compared to control subjects) and evaluate the safety and tolerability of AMG 386 in combination with paclitaxel in the treatment of subjects with advanced recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Primary Outcome Measure:

• Progression free survival (PFS)

Secondary Outcome Measures:

* Object Response Rate (ORR), duration of response (DOR). CA-125 response rate
* Safety and Tolerability
* Change and duration of change on blood levels of CA-125


Options:
A: Arm Label: Paclitaxel & Carboplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: Carboplatin | Arm Label: Paclitaxel & Carboplatin & Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Paclitaxel, Drug: Carboplatin | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Paclitaxel & Carboplatin & Bevacizumab | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Paclitaxel & Carboplatin, Paclitaxel & Carboplatin & Bevacizumab | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Paclitaxel & Carboplatin, Paclitaxel & Carboplatin & Bevacizumab
B: Arm Label: Intraperitoneal bevacizumab+ carboplatin; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Carboplatin, Drug: paclitaxel | Arm Label: Intraperitoneal carboplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: paclitaxel | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Intraperitoneal bevacizumab+ carboplatin | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Intraperitoneal bevacizumab+ carboplatin, Intraperitoneal carboplatin | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): Intraperitoneal bevacizumab+ carboplatin, Intraperitoneal carboplatin
C: Arm Label: Pembrolizumab + paclitaxel ± bevacizumab; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab, Drug: Paclitaxel, Drug: Bevacizumab, Drug: Docetaxel | Arm Label: Placebo + paclitaxel ± bevacizumab; Type: PLACEBO_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: Bevacizumab, Other: Placebo for pembrolizumab, Drug: Docetaxel | Intervention Type: BIOLOGICAL; Name: Pembrolizumab; Assigned to Arm(s): Pembrolizumab + paclitaxel ± bevacizumab | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Pembrolizumab + paclitaxel ± bevacizumab, Placebo + paclitaxel ± bevacizumab | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Pembrolizumab + paclitaxel ± bevacizumab, Placebo + paclitaxel ± bevacizumab | Intervention Type: OTHER; Name: Placebo for pembrolizumab; Assigned to Arm(s): Placebo + paclitaxel ± bevacizumab | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): Pembrolizumab + paclitaxel ± bevacizumab, Placebo + paclitaxel ± bevacizumab
D: Arm Label: Arm A; Type: EXPERIMENTAL; Interventions: Drug: AMG 386, Drug: Paclitaxel | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: AMG 386, Drug: Paclitaxel | Arm Label: Arm C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: AMG 386 Placebo | Intervention Type: DRUG; Name: AMG 386; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: AMG 386; Assigned to Arm(s): Arm B | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm A, Arm B, Arm C | Intervention Type: DRUG; Name: AMG 386 Placebo; Assigned to Arm(s): Arm C

Answer: D